Skip to content

To study how efficacious isâ??Arborium plusâ??Ayurvedic formulation on patients with Varicose veins.

An Open Label, prospective, clinical study to evaluate the efficacy of â??Arborium plusâ?? a proprietary Ayurvedic formulation on Varicose veins.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/02/006689
Enrollment
40
Registered
2016-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients with unilateral & bilateral varicose veins in the lower limbs

Interventions

Intervention1: Arborium plus â?? a patented Ayurvedic Polyherbal formulation: Arborium plus 10ml twice daily after food for 90 days. ( Ingredients of Arborium plus : flower extracts of Rhododendron a

Sponsors

Redhill Herbals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.A potential subject willing to give written informed consent on his own or legally acceptable representative (LAR) /Impartial witness in case of Illiterate subject and comply with all study procedures. 2.Patients with unilateral & bilateral varicose veins in the lower limbs 3.Both male & female patients will be included.

Exclusion criteria

Exclusion criteria: 1.Lower limb varicose vein with deep vein thrombosis,vein calcification,venous ulcer, 2. Lower limb varicose vein with pregnancy 3. Lower limb varicose vein with per abdominal masses 4. Patients with systemic disorders. 5. Age below 20 years and above 60 years 6.Patients with the bleeding disorders.

Design outcomes

Primary

MeasureTime frame
Percentage reduction in the Venous Clinical Severity Score (VCSS)as compared to baseline in varicose vein patientsTimepoint: At Visit-2 (Day 30) and Visit-4 (Day 90)

Secondary

MeasureTime frame
Percentage of subjects who achieve complete or partial response and assessed for overall responseto lower limb Doppler study and haematogical parameters as compared to baselineTimepoint: Visit-4 (Day 90);Safety of the study drug will be estimated from type, number, frequency and percentage of subjects with AE(s) Timepoint: During study period.

Countries

India

Contacts

Public ContactDrRCSatish Kumar

Interdisciplinary School of Indian System of Medicine,SRM University

ilangok67@gmail.com9444144120

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026